A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn*s Disease

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2011
This article has no abstract
Epistemonikos ID: 434428a53d78df601491c359cc26c29c9d6ef26f
First added on: Apr 16, 2025